Growth Stage

AI platform that provides personalized health recommendations based on DNA, labs and environment.

AI platform that provides personalized health recommendations based on DNA, labs and environment.


Raised this Round: Raised: $1,036,802

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Preferred



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Early Bird Valuation


Pre-Money Valuation


Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Los Angeles, California

Business Type


SelfDecode, with a pre-money valuation of $34.9 million, is raising crowdfunding on Wefunder. The company has developed an AI-based platform that analyses DNA, labs, and the environment to provide personalized health recommendations. The SelfDecode platform gives targeted supplement, diet, and lifestyle recommendations to the users. Joseph Cohen founded SelfDecode in April 2019. The proceeds of the current crowdfunding round, with a minimum goal of $50,000 and a maximum goal of $1,069,999, will be used for marketing, product development, and hiring. SelfDecode works on a recurring revenue model and generates a predictable revenue stream from subscriptions. The revenues of the company grew by 360% from the fourth quarter of 2019 to the fourth quarter of 2020.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 07/18/2021
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
SelfDecode 04/29/2023 Wefunder $52,498,168 $341,985 Equity - Preferred Funded RegCF
SelfDecode 04/29/2022 Wefunder $34,948,219 $1,036,802 Equity - Preferred Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article


With ever-improving medical technology and unprecedented access to information, consumers are taking a greater interest in their health. They want sophisticated, flexible, customized care. To meet the demand, the healthcare industry is exploring solutions to give consumers comprehensive knowledge about their personal health. One such method is genomic analysis, which is analysis based on an individual’s DNA. Genomic analysis can reveal a person’s risk of developing hereditary diseases (including hereditary cancers), genetic disorders, diabetes, lactose intolerance levels and more. 

SelfDecode is tapping into genomic analysis and AI to help consumers improve their health. The company produces wellness reports and gives customized health recommendations based on DNA, microbiome, environmental factors and lab test results. SelfDecode has its own DNA testing kit and also supports files from other DNA testing kits such as 23andMe, Ancestry, and MyHeritage

SelfDecode’s current WeFunder raise has been rated a Deal to Watch by the KingsCrowd investment team.

Next Section: Price


SelfDecode is offering preferred equity at a pre-money valuation of $34.9 million. This valuation is appropriate for the stage SelfDecode is in. The company generated $1.4 million in revenue in 2020, an increase of 18% from the previous year. This gives SelfDecode an attractive revenue multiple for a software company. On top of that, this valuation also takes into account the high quality of SelfDecode’s technology. Overall, SelfDecode is being valued fairly and receives a high price score.

Next Section: Market


In 2020, the global genomics market was worth $20.1 billion with a compound annual growth rate of 15.4%. North America dominates the market with a share of 36.7%. 

The genomics market is still considered relatively young. Researchers are still investigating the value and benefits of gene-based medicine. Some researchers feel it should be treated with caution, and others state it is not always effective. But overall, the market size and the rapid growth rate show a promising future. It is a reflection of an increasing market acceptance by the public. Therefore, SelfDecode receives an impressive market score.

Next Section: Team


SelfDecode founder and CEO Joe Cohen has a formal education in finance, psychology, and premed from Brooklyn College. He started SelfDecode in January 2016 and concurrently runs two other businesses, and LabTestAnalyzer. Running three businesses at the same time can indicate that a founder is not dedicated. Though the three companies are under the same parent company, GeniusLabs, Cohen’s attention is still divided. And while Cohen’s eight years of experience running these businesses put him in a good position to lead the company, there was no other information regarding his prior experience that can further validate his ability to make SelfDecode a successful company. He also has no experience bringing a company to an exit.

Cohen assembled a strong and well-rounded team to expand SelfDecode’s reach. SelfDecode currently has 88 team members that cover expertise in software architecture, engineering, science, finance, operations, customer support, human resources, product management, and marketing. One notable member of leadership is Chief Science Officer Puya Yazdi. His years of experience in the healthcare industry and passion for genomics are crucial for the accuracy of SelfDecode’s main product. Overall, the well-rounded team and the founder’s lack of dedication and exit experience gave SelfDecode a roughly average team score. 

Next Section: Differentiators


Some of SelfDecode’s mature competitors include 23andMe, Ancestry, and MyHeritage. Tons of traditional health coaches are indirect competitors. However, this should pose no problem because other DNA testing kits are more of a complementary product instead of direct competition. Additionally, SelfDecode’s main selling point is its AI doctor feature that gives personalized DNA-based health recommendations to its users, which has a unique advantage over traditional health coaches. The closest competitor is CircleDNA, which offers very similar products with 20 health categories and more than 500 reports. But while CircleDNA does provide some health advice, SelfDecode seems to offer more comprehensive recommendations. SelfDecode also stands out because it provides a score on how specific genes correlate with different health traits. Compared to competitors like 23andMe, SelfDecode gets the most complete picture of its users’ DNA. 

However, SelfDecode’s pricing is not highly differentiated. Its tiered pricing system is similar to 23andMe and Ancestry. It also lacks patent protection, which makes its product less defensible. Overall, SelfDecode’s differentiator score is slightly above average. 

Next Section: Performance


Since its incorporation in 2019, SelfDecode has performed remarkably well using a direct-to-consumer model, offering its service through its own website. According to its pitch deck, SelfDecode generated $1.9 million in revenue in 2020. This doesn’t match the $1.4 million in 2020 revenue listed in its Form C. But according to its Form C, it generated more than $2 million in revenue from 2019 to 2020, which is a strong performance.

Although SelfDecode is not profitable yet and still burns quite a bit of cash, it has received high praise from its customers. The company also has an impressively high monthly retention rate of 98% and 123,000 active subscribers on its email list. Its customer lifetime value over customer acquisition cost ratio is five times, which means that the company is growing fast. Additionally, SelfDecode has received nearly $5 million in prior investment rounds. Overall, its impressive performance thus far receives a high rating.

Next Section: Risks


On top of not having a prior exit, Joe Cohen is the sole founder of SelfDecode. This can present a risk of limited network and expertise, though it certainly hasn’t hurt SelfDecode’s prospects thus far. SelfDecode currently has some short-term and long-term debt, and the nature of its business requires it to spend a lot of money. Both of these factors can cause it to burn even more cash and hurt its finances if not managed properly.

SelfDecode is aiming to expand beyond the direct-to-consumer model and into a business-to-business model in the near future. However, it will take a long time to scale into this production as the company is still developing the platform in order to license to healthcare organizations. Moreover, selling to healthcare organizations will require a long sales cycle.

Next Section: Bearish Outlook

Bearish Outlook

SelfDecode is operating in a competitive, rapidly growing market. Although its huge amount of data makes it defensible, it lacks patent protection for its services. Defensibility is crucial as leaders in DNA testing kits like 23andMe could comfortably enter the market and offer the same health recommendation services to its wide customer base. This potential future might be a huge obstacle in SelfDecode’s quest to scale and grab more market share. Additionally, SelfDecode’s services may not have staying power. Customers may only use the SelfDecode platform for a few years and stop paying for it once they develop the habits recommended by the service. It could be a challenge for SelfDecode to sustain its retention rate. 

The revenue presented on SelfDecode’s raise page and its Form C seems to belong to SelfDecode’s parent company, GeniusLabs. This could indicate a less impressive revenue number for SelfDecode. Founder Joe Cohen is also currently developing a fourth company, a supplement company called Jo. This makes the company seem unfocused. And because its other companies are not well established yet and its platform for the business-to-business model is still under development, its future is uncertain.

Next Section: Bullish Outlook

Bullish Outlook

Despite potential obstacles, SelfDecode has grown substantially over the past two years. The fact that it has a sizable team full of competent members shows that the business is in it for the long run. SelfDecode’s product has some key differentiators that set it apart from the competition, including an AI doctor feature and a comprehensive view of its users’ health. It also has licensed professionals to support its customers.

SelfDecode has been growing steadily year over year, and that seems unlikely to change. It currently aims to reach $4 million in revenue by the end of this year, which is a feasible goal. It has generated more than $2 million in revenue since 2019, which is a sign of positive traction. It also has a substantial retention rate of 98% and glowing customer reviews, which bode well for the product. 

While challenges lie ahead, SelfDecode has potential because its market is likely to continue growing at a rapid pace. As genomic analysis becomes more widely practiced, SelfDecode is well-positioned to profit as a comprehensive health service. Additionally, SelfDecode’s business-to-business model could play a huge role in scaling the company and solidifying its place in the market.

Next Section: Executive Summary

Executive Summary

SelfDecode uses AI to provide personalized, DNA-based health recommendations. It incorporates factors such as genetics, microbiome, and environment to produce accurate health and wellness reports specific to each user. SelfDecode is in a competitive yet rapidly growing global genomics market. Hence, making its service defensible will be key for SelfDecode to become a leader in this market. It is a part of a parent company, GeniusLabs, which has two other businesses and is developing another. SelfDecode has an impressively large team that seems well-positioned to scale the business, and the company has shown steady growth year over year. SelfDecode also distinguishes itself by providing the most comprehensive and customized health and wellness reports among its competitors. Therefore, SelfDecode is a Deal to Watch.

For questions regarding the KingsCrowd staff pick or ratings for this company, please reach out to

Analysis written by Inez Sanjaya.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
SelfDecode on Wefunder 2021
Platform: Wefunder
Security Type: Equity - Preferred
Valuation: $34,948,219
Price per Share: $2.36

Follow company

Follow SelfDecode on Wefunder 2021

Buy SelfDecode's Deal Report

Warning: according to the close date for this deal, SelfDecode may no longer be accepting investments.

SelfDecode Deal Report

Get KingsCrowd’s comprehensive report on SelfDecode including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether SelfDecode is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the SelfDecode deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge